Kalaris Therapeutics, Inc.

KLRS

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Redmile Group RTW Investments

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Redmile GroupNEWFeb 17, 2026

Shares: 82,955Value: $700K

# SIGNAL NOTE: Redmile Group Initiates KLRS Position Redmile's $700K entry into Kalaris suggests conviction in its lead program KLR-01 (a small-molecule inhibitor targeting fibrotic diseases), likely ahead of near-term clinical readouts expected in 2024-2025. The crossover specialist's initiation may signal confidence in the company's pathway to differentiation in idiopathic pulmonary fibrosis (IPF) or related indications where unmet need remains despite existing therapies. Timing and position size warrant monitoring for upcoming clinical catalysts.

RTW InvestmentsNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

COGT2 funds NGNE2 funds REPL2 funds STOK2 funds BEAM2 funds NBIX1 fund FDMT1 fund ALURW

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: RTW Investments Enters KLRS** RTW's $11M initiation in Kalaris suggests confidence in the company's clinical pipeline, likely driven by upcoming data readouts or positive trial momentum. Kalaris is advancing KLS-580, a selective androgen receptor modulator (SARM) for muscle wasting/sarcopenia—a large indication with limited approved therapies. Watch for Phase 2 readouts in 2024-2025 as a near-term catalyst; data quality and competitive positioning versus other SARMs in development will determine risk/reward.